Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

development 5,519 4,987 24,198 21,484

Marketing, general and

administrative 2,042 1,527 8,429 5,787

Total operating expenses 7,561 6,514 32,627 27,271

Loss from operations (7,511) (6,508) (32,561) (27,249)

Interest income 787 434 3,390 1,994

Interest expense (1,483) -- (5,135) --

Other expense, net (26) (19) (30) (50)

Loss before income taxes (8,233) (6,093) (34,336) (25,305)

Income tax provision (benefit) (74) 8 (343) 42

Net loss ($8,159) ($6,101) ($33,993)($25,347)

Basic and diluted loss per share(1) ($1.18) ($0.92) ($5.05) ($3.83)

Weighted-average number of shares

of common stock outstanding(1) 6,898 6,628 6,737 6,620

(1) Adjusted for all periods presented to reflect the Company's

one-for-ten reverse stock split effected February 20, 2008.

CONDENSED CONSOLIDATED BALANCE SHEET DATA

December 31,

(In thousands) 2007 2006

Cash and cash equivalents $61,067 $30,914

Total assets 63,195 31,856

Convertible senior notes 54,275 --

Total liabilities 61,988 6,402

Shareholders' equity 1,207 25,454


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 •    First of its ... for sustainability ,     New facility will help solve ... , Syngenta unveiled its new crop research ... company’s RTP Innovation Center. The first of its kind, ... simulate any agricultural climate and precisely measure plant inputs ...
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... 2013 Men’s skin is biologically different than ... ) and has been known to react more aggressively when ... be far from puberty, other acne causing factors like P.acnes ... and threatening skin with unsightly acne scars. Adult acne treatment, ... Health on how to reduce and prevent acne scarring. ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... Decision Resources, one of the world,s leading research and advisory ... uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors ... billion in 2008 to $5.2 billion in 2018 in the ... Japan. , The new Pharmacor report entitled ...
... ... and related products. Wide range of new peptide synthesis reagents and catalogue peptides. New ... , ... October 22, 2009 -- Mimotopes Pty Ltd, a subsidiary of Commonwealth Biotechnologies Inc. (NASDAQ ...
... , MONTREAL, Oct. 23 /PRNewswire/ - Enerkem, a leading ... Corporate Knights 2009 Next 10 Emerging Cleantech Leaders. Vincent ... the other Cleantech companies at today,s Toronto Stock Exchange ... Cleantech Next 10 list features Canada,s best privately held ...
Cached Biology Technology:Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market 2Mimotopes Launches Online Peptide Superstore 2Mimotopes Launches Online Peptide Superstore 3Enerkem Named an Emerging Cleantech Leader in Canada 2
(Date:5/16/2013)... us don,t ponder our pulses outside of the gym. But ... monitor heart health. , Zhenan Bao, a professor of chemical ... a dollar bill and no wider than a postage stamp. ... the wrist, is sensitive enough to help doctors detect stiff ... be used to continuously track heart health and provide doctors ...
(Date:5/16/2013)... May 16, 2013 The consultancy ... on Tuesday to Germany,s largest ... border control system. DERMALOG has been honored ... Practices Award in the category Global Biometrics and Border ... Biometric   Border Control System . One of ...
(Date:5/15/2013)... that have powerful behavioral effects on diverse organisms ... ecosystems, according to a theory proposed in the ... of the theory, Ryan P. Ferrer of Seattle ... University of California at Los Angeles, liken such ... may be uncommon but exert a controlling influence, ...
Breaking Biology News(10 mins):Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3Global Biometrics and Border Control Award for DERMALOG 2Global Biometrics and Border Control Award for DERMALOG 3Global Biometrics and Border Control Award for DERMALOG 4Natural 'keystone molecules' punch over their weight in ecosystems 2
... Partnership, in partnership with the LUNGevity Foundation, is pleased ... grant competition. The research grants, each $100,000, ... biology, risk assessment, prevention, detection, and response to treatment. ... generous donors, were able to offer researchers critical funding ...
... LAKE CITY Two major eye diseases and leading causes ... or even prevented by drugs that activate a protein ... of Utah School of Medicine and several other institutions ... both diseases was prevented and even reversed when the ...
... a systems biological analysis of genome-scale data from ... researchers identified that the master gene controlling the ... study will appear in the latest issue of ... This hypothesis derived from multi-network analysis of Arabidopsis ...
Cached Biology News:National Lung Cancer Partnership and LUNGevity Foundation 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 3Systems biology approach identifies nutrient regulation of biological clock in plants 2
...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Human Cell Line Slides...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Biology Products: